Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results
2011 | 83 | 8 | 424-429

Article title

Determination of the Activity of CD134 (OX-40) and CD137 (4-1BB) Adhesive Nolecules by Means of Flow Cytometry in Patients with Colorectal Cancer Metastases to the Liver


Title variants

Languages of publication



Colorectal carcinoma (CRC) is one of the most common reasons of mortality in patients diagnosed with neoplasms. In nearly 20% of patients with colorectal carcinoma metastatic lesions are diagnosed. In general, survival of patients with metastatic lesions to the liver and other organs is poor. Conventional therapy of colorectal carcinoma is based on the surgical excision of the tumor, chemotherapy, and radiotherapy.The aim of the study was to determine the expression of CD134 and CD137 molecules inside the tumor, at the border of the tumor, in the healthy tissue, and peripheral blood, considering patients with colorectal carcinoma metastases to the liver.Material and methods. The study group comprised 39 patients subject to surgical treatment at the Department of General and Gastroenterological Surgery, due to colorectal carcinoma with liver metastases. CD134 and CD137 adhesive molecule levels were determined inside the tumor, at the border of the tumor, and in the healthy margins of the surgical incision. Additionally, the authors evaluated the peripheral blood level of the above-mentioned molecules on the day of the surgical procedure, and 10 days, thereafter.Results. The mean CD134 levels were the highest inside the tumor, significantly decreasing towards the direction of healthy tissues. The average peripheral blood molecule levels were four-fold higher on the day of the surgical procedure, as compared to values obtained on the tenth postoperative day. This dependency also concerned the remaining statistical measures.The mean CD137 levels showed no significant difference, regardless their location. The authors observed significant, peripheral blood, CD137 level differences, considering the day of the surgical procedure and tenth postoperative period. The mean CD137 peripheral blood level was several times higher on the day of the surgical procedure, as compared to the postoperative period.Conclusions. The determination of the activity of CD134 and CD137 molecules might create opportunities to plan treatment and predict prognosis in case of colorectal carcinoma. Proper immuno-therapeutic management which is based on the expression of the above-mentioned molecules might help determine the risk of metastases, preventing from their development. In advanced cases treatment of liver metastases might be possible.









Physical description


1 - 8 - 2011
4 - 10 - 2011


  • 2nd Department of General and Gastroenterological Surgery, Medical University in Białystok
  • 2nd Department of General and Gastroenterological Surgery, Medical University in Białystok
  • 2nd Department of General and Gastroenterological Surgery, Medical University in Białystok
  • Department of Clinical Immunology, Medical University in Białystok
  • 2nd Department of General and Gastroenterological Surgery, Medical University in Białystok


  • Chen S-H, Pham-Nguyen KB, Marinet O et al.: Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Molecular Therapy 2000; 2(1): 39-46.[Crossref]
  • Mazollini G, Murillo O, Atorrasagasti C et al.: Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol 2007; 13(44): 5822-31.
  • Petty JK, He K, Corless CL et al.: Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg 2002; 183: 512-18.
  • Tebutt NC, Cattell E, Midgley R et al.: Systemic treatment of colorectal cancer. Eur J Cancer 2002; 38: 1000-15.[Crossref]
  • Mayer-Kuckuk P, Banerjee D, Kemeny N et al.: Molecular therapies of colorectal cancer metastatic to the liver. Molecular Therapy 2002; 5(5): 492-500.[Crossref]
  • Cragg MS, French RR, Glennie MJ: Signaling antibodies in cancer therapy. Cancer 1999; 11: 541-47.
  • Vonderheide RH, June CH: A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cells immunotherapy. Immunol Res 2003; 27: 341-56.[Crossref][PubMed]
  • Weinberg AD, Rivera M-M, Prell R et al.: Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunology 2000; 164: 2160-69.
  • Marinet O, Ermekova V, Qiao JQ et al.: Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in mouse model. Journal of the National Cancer Institute 2000; 92(11): 931-36.[Crossref]
  • Croft M: Costimulation of T cells by OX-40, 4-1BB, and CD27. Cytokine Growth Factor Rec 2003; 14: 265-73.
  • Pan P-Y, Zang Y, Weber K et al.: OX40 ligation enhances primary and memory cytotoxic L lymphocyte responses in an immunotherapy for hepatic colon metastases. Molecular Therapy 2002; 6(4): 528-36.[Crossref]
  • Tirapu I, Arina A, Mazollini G et al.: Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with colon cancer with anti-CD-137 monoclonal antibodies and alloantigens. Int J Cancer 2004;110: 51-60.[Crossref]
  • Dimberg J, Hugander A, Wagsater D: Expression of CD137 and CD137 ligand in colorectal cancer patients. Oncology Reports 2006; 15: 1197-1200.
  • Zhang N, Sadun RE, Arias RS et al.: Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clinical Cancer Research 2007,; 13: 2758-67.[WoS]
  • Cepowicz D, Stasiak-Barmuta A, Zalewski B et al.: Assessment expresion of the adhesion molecules, CD134 and CD137, In patients with colorectal cancer by flow cytometry. Annales Academiae Medicae Bialostocensis 2004; 49 (suppl 1): 34-36.
  • Ballestrero A, Boy D, Moran E et al.: Immunotherapy with dendritic cells for cancer. Advanced Drug Delivery Reviews 2008; 60: 173-83.[Crossref][PubMed][WoS]
  • Mocellin S, Nitti D: Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. Medicinal Research Reviews 2008; 28(3): 413-44.[PubMed][WoS][Crossref]
  • Sanz L, Blanco B, Alvarez-Vallina L: Antibodies and gene therapy: teaching old ‘magic bullets’ new trics. Trends in immunology 2004; 25(2): 85-91.[Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.